Factors predictive of successful darunavir/ritonavir-based therapy in highly antiretroviral-experienced HIV-1-infected patients (the DARWEST study).

@article{Delaugerre2010FactorsPO,
  title={Factors predictive of successful darunavir/ritonavir-based therapy in highly antiretroviral-experienced HIV-1-infected patients (the DARWEST study).},
  author={Constance Delaugerre and Jean François Buyck and Gilles Peytavin and Jean Paul Viard and Marie Laure Chaix and David Zucman and Emmanuel Mortier and St{\'e}phane Blanche and Elisabeth Rouveix and Gilles Force and Philippe Aegerter and Pierre de Truchis},
  journal={Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology},
  year={2010},
  volume={47 3},
  pages={
          248-52
        }
}
BACKGROUND Darunavir (DRV) is the latest protease inhibitor (PI) to be approved for antiretroviral-naive and -experienced HIV-infected patients. OBJECTIVES We examined virologic and immunologic outcomes of highly antiretroviral-experienced patients with triple-class drug resistance receiving DRV/r-based regimens, and attempted to identify factors predictive of virologic success. STUDY DESIGN We studied patients beginning a ritonavir-boosted DRV (DRV/r 600/100mg twice daily)-containing… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-3 of 3 citations

References

Publications referenced by this paper.
Showing 1-10 of 27 references

Safety and efficacy of darunavir (TMC114) with low-dose ritonavir in l Virology

  • JM Molina, C Cohen, C Katlama, B Grinsztejn, A Timerman, J Pedro Rde
  • J Acquir Immune Defic Syndr ;46:24–31
  • 2010

Low rate of tipranavir and darunavir resistance mutations in PI-experienced patients using the new interpretation scores - implications for PI sequencing

  • C Garrido, E Poveda, A Corral, C De Mendoza, V. Soriano
  • XVII international HIV drug resistance
  • 2008

Mutations selected by other protease inhibitors predict durable response to tipranavir in treatment-experienced patients

  • DB Hall, J Baxter, J Schapiro, CAB Boucher, C Tilke, J. Scherer
  • XVII international HIV drug resistance
  • 2008

Phenotypic and genotypic determinants of resistance to darunavir : analysis of data from treatment - experienced patients in POWER 1 , 2 , 3 and DUET - 1 and 2

  • S DeMeyer, I Dierynck, E Lathouwers, B VanBaelen, T Vangeneugden, S Spinosa-Guzman
  • 2008

Phenotypic and genotypic determinants of resistance to darunavir: analysis of data from treatment-experienced patients in POWER 1,2,3 and DUET-1 and 2. In: XVII international HIV drug resistance

  • S De Meyer, I Dierynck, E Lathouwers, B Van Baelen, T Vangeneugden, S SpinosaGuzman
  • 2008